Eli Lilly stock ran on a story that was public and dated long before the price moved, and reading it right still would not have put you ahead of every peer. Revenue rose 56% year over year in the first quarter of 2026, non-GAAP earnings per share reached $8.55 against $3.34 a year earlier, and the non-GAAP performance margin hit 50%, roughly seven percentage points above the prior-year quarter. Management raised full-year 2026 revenue guidance by $2 billion and tied that raise to strong underlying performance in the quarter rather than to the new medicine, which had three weeks of data at the time. Nine months before the run began, the CEO had already sized the eventual market at roughly a billion people and argued a large share of them can only be reached with a pill; Foundayo reached pharmacies about seventeen months later. Within weeks the company counted more than 20,000 patients treated, four in five of those prescriptions new to the class. As of the last report before the run, trailing-twelve-month revenue was $49.0 billion and growing 36% year over year, against a 20% average over the prior three fiscal years, and trailing operating margin was 40%, versus a 32% three-year average; management had announced over $50 billion of new U.S. manufacturing investment since 2020.
Eli Lilly and CompanyEli Lilly's strong Q1 earnings and raised guidance are the subject of the article.
Amgen Inc
Johnson & Johnson
Merck & Company Inc
Pfizer Inc